CliffBio
small molecule

ATRIPLA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Loss of exclusivityApril 2029latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameATRIPLA
Active ingredientEFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Strength600MG;200MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2006
Marketing statusDISCN

Listed patents

PatentExpiresType
8598185April 2029product
9018192June 2026use U-1170
9545414June 2026product

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ATRIPLA patent cliff — loss of exclusivity April 2029 | CliffBio